Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Vitamin B, while harmless, does not help prevent a repeat occurrence of strokes or heart attacks, according to a study released Wednesday.
The findings, based on first-ever clinical trials, suggest that vitamin B supplements should no longer be recommended for patients who have suffered severe vascular events, the researchers said.
Previous research has shown a link between an increase of amino acid in the blood - a condition known as homocysteine - and a higher risk of stroke and cardiovascular disease.
At the same time, other studies have shown that a daily dose of B vitamins can reduce abnormal amino acid levels.
What remained unknown was whether the supplements would also help cut the risk of repeat heart attacks or strokes, fatal or non-fatal.
To find out, an international consortium of doctors and scientists in 20 countries conducted a clinical trial with more than 8,000 patients who had recently had a serious heart or vascular problem.
Half the participants were given a daily dose of B vitamins - a mix of folic acid, B6 and B12 - while the other half swallowed lookalike placebos.
During a follow-up period that averaged 3.4 years, there was no statistically significant difference in the outcome: 15 percent of the vitamin B group experienced a major vascular event, compared to 17 percent for the control group.
At the same time, the vitamins did not cause any unwanted side effects.
The results were published in the British medical journal The Lancet.
mh/ss
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments